NASDAQ$VERV
Verve Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Verve Therapeutics reported its Q1 2024 financial results and pipeline progress.
Verve Therapeutics reported a net loss of $48.7 million for the first quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $606.4 million, expected to fund operations into late 2026. They also achieved the first milestone payment from Eli Lilly for collaboration on an in vivo gene editing program targeting lipoprotein(a) (Lp(a)).
- First patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102.
- VERVE-201 clinical trial initiation is on track for the second half of 2024.
- Received first milestone payment from Eli Lilly for collaboration on an in vivo gene editing program targeting lipoprotein(a) (Lp(a)).
- Cash, cash equivalents and marketable securities of $606.4 million; cash runway into late 2026.
Headline financials
Revenue & EPS history
Verve Therapeutics · Revenue · Quarterly
$5.7M
Revenue by segment
Verve Therapeutics · $3.12M total across 1 segment · Q3 2023
- Collaboration Revenue$3.12M—100.0%
Forward guidance
Verve expects to provide a data update on the PCSK9 program in 2025 and continues to expect its capital position to be sufficient to fund its operations into late 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q1 2024
-1.0%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-3.8%
Avg return
30 days after
47%
8 / 17 earnings
Positive
+24.4%
Q4 2023
Best reaction
-34.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +3.4% | +5.0% | +48.1% | |
| Q4 2025 | -1.7% | -2.9% | -16.3% | |
| Q3 2024 | +6.0% | +4.5% | +1.0% | |
| Q2 2024 | -12.1% | -20.8% | -1.6% | |
| Q1 2024 | +3.2% | +0.8% | -15.6% | |
| Q4 2023 | +24.4% | +12.7% | -8.2% | |
| Q3 2023 | +11.8% | +4.8% | -13.8% | |
| Q2 2023 | +2.6% | -9.9% | -28.0% | |
| Q1 2023 | -5.2% | -4.5% | -2.6% | |
| Q4 2022 | +7.0% | +3.0% | -20.8% | |
| Q3 2022 | -34.2% | -13.7% | -31.5% | |
| Q2 2022 | +17.5% | +31.2% | +47.0% | |
| Q1 2022 | -4.4% | +12.8% | +15.2% | |
| Q4 2021 | -20.1% | -4.3% | -19.7% | |
| Q3 2021 | -2.7% | -7.8% | -34.7% | |
| Q4 2020 | -1.4% | +5.5% | +7.5% | |
| Q2 2021 | -10.7% | -11.9% | +10.1% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro